Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney

J Urol. 1997 Jul;158(1):245-7. doi: 10.1097/00005392-199707000-00079.


Purpose: To evaluate retrospectively c-erbB-2 oncogene amplification in paraffin embedded specimens of collecting duct carcinoma of the kidney (CDC) with competitive polymerase chain reaction (PCR).

Materials and methods: Eleven CDC specimens were evaluated with a novel PCR procedure for oncogene amplification measurement, which provides sensitive and accurate results even in presence of low-quality DNA, unsuitable for Southern blot techniques.

Results: c-erbB-2 oncogene amplification was present in 5 out of 11 cases (45%) with a number of copies ranging from 4 to 12. All patients presenting oncogene amplification decreased within one year, while 50% (3/6) of those without amplification are alive with a mean follow-up of 42 months.

Conclusions: The high incidence of c-erbB-2 oncogene amplification in CDC further characterizes this tumor as a separate entity from renal cell carcinoma, and shows some genetic characteristics in common with transitional cell carcinoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Genes, erbB-2*
  • Humans
  • Kidney Neoplasms / genetics*
  • Kidney Tubules, Collecting*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction / methods*
  • Retrospective Studies